Melittin: a venom-derived peptide with promising anti-viral properties.

Hamed Memariani, Mojtaba Memariani, Hamideh Moravvej, Mohammad Shahidi-Dadras
Author Information
  1. Hamed Memariani: Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  2. Mojtaba Memariani: Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. memaryani@gmail.com. ORCID
  3. Hamideh Moravvej: Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  4. Mohammad Shahidi-Dadras: Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Abstract

Despite tremendous advances in the development of anti-viral therapeutics, viral infections remain a chief culprit accounting for ongoing morbidity and mortality worldwide. Natural products, in particular animal venoms, embody a veritable cornucopia of exotic constituents, suggesting an immensurable source of anti-infective drugs. In this context, melittin, the principal constituent in the venom of the European honeybee Apis mellifera, has been demonstrated to exert anti-cancer, anti-inflammatory, anti-diabetic, anti-infective, and adjuvant properties. To our knowledge, there is no review appertaining to effects of melittin against viruses, prompting us to synopsize experimental investigations on its anti-viral activity throughout the past decades. Accumulating evidence indicates that melittin curbs infectivity of a diverse array of viruses including coxsackievirus, enterovirus, influenza A viruses, human immunodeficiency virus (HIV), herpes simplex virus (HSV), Junín virus (JV), respiratory syncytial virus (RSV), vesicular stomatitis virus (VSV), and tobacco mosaic virus (TMV). However, medication safety, different routes of administrations, and molecular mechanisms behind the anti-viral activity of melittin should be scrutinized in future studies.

Keywords

References

  1. J Drug Target. 2003;11(8-10):525-30 [PMID: 15203921]
  2. Pharmaceuticals (Basel). 2013 Nov 28;6(12):1543-75 [PMID: 24287494]
  3. Expert Rev Proteomics. 2017 Oct;14(10):931-939 [PMID: 28879805]
  4. Virology. 1993 Oct;196(2):548-56 [PMID: 8396802]
  5. Expert Rev Anti Infect Ther. 2011 Jan;9(1):49-59 [PMID: 21171877]
  6. Trends Microbiol. 2004 Aug;12(8):353-6 [PMID: 15276609]
  7. Antiviral Res. 2013 Feb;97(2):218-21 [PMID: 23261846]
  8. Chem Biol Drug Des. 2017 Mar;89(3):327-338 [PMID: 27591703]
  9. Curr Med Chem. 2004 Dec;11(23):3029-40 [PMID: 15578997]
  10. Clinicoecon Outcomes Res. 2014 Apr 25;6:217-25 [PMID: 24812523]
  11. Drug Dev Ind Pharm. 2018 Jun;44(6):982-987 [PMID: 29325460]
  12. Eur J Clin Microbiol Infect Dis. 2000 Mar;19(3):187-94 [PMID: 10795591]
  13. Microb Pathog. 2018 Jun;119:72-80 [PMID: 29626660]
  14. Appl Microbiol Biotechnol. 2019 Apr;103(8):3265-3276 [PMID: 30824944]
  15. Curr Med Chem. 2012;19(31):5239-77 [PMID: 22934774]
  16. Bioorg Med Chem. 2018 Jun 1;26(10):2738-2758 [PMID: 28988749]
  17. Clin Ther. 2002 Jan;24(1):38-58 [PMID: 11833835]
  18. Arch Virol. 2018 Feb;163(2):299-317 [PMID: 29058149]
  19. J Clin Invest. 2009 Sep;119(9):2830-42 [PMID: 19726870]
  20. J Gen Virol. 2017 Jan;98(1):2-3 [PMID: 28218572]
  21. J Immunol Methods. 2014 Jul;409:131-46 [PMID: 24291345]
  22. Biophys J. 1997 Aug;73(2):831-8 [PMID: 9251799]
  23. Arch Biochem Biophys. 1990 Dec;283(2):249-57 [PMID: 2177321]
  24. Front Microbiol. 2018 Aug 03;9:1751 [PMID: 30123198]
  25. Peptides. 2011 Jul;32(7):1518-25 [PMID: 21620914]
  26. Expert Opin Pharmacother. 2002 Aug;3(8):1199-210 [PMID: 12150697]
  27. Curr Opin Virol. 2016 Jun;18:9-13 [PMID: 26897058]
  28. Nat Med. 1999 Oct;5(10):1110-3 [PMID: 10502801]
  29. Toxicon. 2012 Mar 15;59(4):464-71 [PMID: 21194543]
  30. Emerg Infect Dis. 2006 Jan;12(1):15-22 [PMID: 16494711]
  31. J Biol Chem. 1982 Jun 10;257(11):6016-22 [PMID: 7076662]
  32. Front Microbiol. 2018 Mar 22;9:526 [PMID: 29623073]
  33. Clin Chest Med. 2017 Mar;38(1):29-36 [PMID: 28159159]
  34. Nat Rev Microbiol. 2018 Feb 12;16(3):125-142 [PMID: 29430005]
  35. Proc Natl Acad Sci U S A. 2013 Aug 27;110(35):14243-8 [PMID: 23940362]
  36. Intervirology. 1983;20(1):56-60 [PMID: 6307921]
  37. Biochim Biophys Acta. 1990 May 7;1031(2):143-61 [PMID: 2187536]
  38. Int J Genomics. 2016;2016:9543274 [PMID: 27314006]
  39. Viruses. 2012 Oct 19;4(10):2317-39 [PMID: 23202466]
  40. J Biol Chem. 2008 Dec 5;283(49):33854-7 [PMID: 18819911]
  41. Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):12466-9 [PMID: 8618922]
  42. Int J Antimicrob Agents. 2004 Apr;23(4):382-9 [PMID: 15081088]
  43. Biosci Rep. 2007 Oct;27(4-5):189-223 [PMID: 17139559]
  44. Peptides. 1997;18(2):177-83 [PMID: 9149288]
  45. Biochem Biophys Res Commun. 2016 Oct 7;479(1):103-8 [PMID: 27622323]
  46. Microb Pathog. 2017 Nov;112:57-62 [PMID: 28943153]
  47. Molecules. 2016 May 11;21(5): [PMID: 27187328]
  48. Mol Gen Genet. 1988 Mar;211(3):520-5 [PMID: 2835637]
  49. PLoS Negl Trop Dis. 2013 Dec 26;7(12):e2614 [PMID: 24386500]
  50. FEBS Lett. 1992 Sep 14;309(3):235-41 [PMID: 1516693]
  51. Sci Rep. 2018 Sep 26;8(1):14420 [PMID: 30258185]
  52. Front Microbiol. 2017 Nov 28;8:2249 [PMID: 29238324]
  53. Lancet. 2001 May 12;357(9267):1513-8 [PMID: 11377626]
  54. Proc Natl Acad Sci U S A. 1980 Feb;77(2):847-51 [PMID: 6153806]
  55. Arch Virol. 2016 Aug;161(8):2351-60 [PMID: 27216929]
  56. AIDS. 1990 Mar;4(3):199-206 [PMID: 1693515]
  57. Expert Rev Cardiovasc Ther. 2005 Mar;3(2):193-206 [PMID: 15853593]
  58. Methods Mol Biol. 2017;1602:251-273 [PMID: 28508225]
  59. Biochemistry. 1982 Feb 2;21(3):461-5 [PMID: 7066299]
  60. Tierarztl Prax Ausg K Kleintiere Heimtiere. 2016 Dec 5;44(6):417-423 [PMID: 27808347]
  61. Lancet. 2010 May 1;375(9725):1545-55 [PMID: 20399493]
  62. Proc Natl Acad Sci U S A. 1979 Nov;76(11):5843-7 [PMID: 93283]
  63. Environ Toxicol Pharmacol. 2013 Sep;36(2):697-705 [PMID: 23892471]
  64. J Gen Virol. 1998 Apr;79 ( Pt 4):731-40 [PMID: 9568968]
  65. Antivir Ther. 2013;18(1):95-103 [PMID: 22954649]
  66. J Microbiol. 2016 Dec;54(12):853-866 [PMID: 27888461]
  67. Science. 1972 Jul 28;177(4046):314-22 [PMID: 4113805]
  68. J Hosp Infect. 2018 Dec;100(4):463-468 [PMID: 29614245]
  69. Emerg Microbes Infect. 2012 Dec;1(12):e46 [PMID: 26038413]
  70. Nat Commun. 2019 Mar 29;10(1):1413 [PMID: 30926773]
  71. Antiviral Res. 2008 Apr;78(1):132-9 [PMID: 18054395]
  72. Trends Mol Med. 2004 May;10(5):210-6 [PMID: 15121047]
  73. Angew Chem Int Ed Engl. 2017 May 15;56(21):5931-5936 [PMID: 28444849]
  74. J Gen Virol. 2017 Aug;98(8):1999-2000 [PMID: 28786782]
  75. J Virol. 2013 Sep;87(18):10139-47 [PMID: 23843635]

MeSH Term

Animals
Antiviral Agents
Melitten
Mice
Peptides
Viruses

Chemicals

Antiviral Agents
Peptides
Melitten

Word Cloud

Created with Highcharts 10.0.0virusanti-viralmelittinvirusesactivityanti-infectivepropertiesDespitetremendousadvancesdevelopmenttherapeuticsviralinfectionsremainchiefculpritaccountingongoingmorbiditymortalityworldwideNaturalproductsparticularanimalvenomsembodyveritablecornucopiaexoticconstituentssuggestingimmensurablesourcedrugscontextprincipalconstituentvenomEuropeanhoneybeeApismelliferademonstratedexertanti-canceranti-inflammatoryanti-diabeticadjuvantknowledgereviewappertainingeffectspromptingussynopsizeexperimentalinvestigationsthroughoutpastdecadesAccumulatingevidenceindicatescurbsinfectivitydiversearrayincludingcoxsackievirusenterovirusinfluenzahumanimmunodeficiencyHIVherpessimplexHSVJunínJVrespiratorysyncytialRSVvesicularstomatitisVSVtobaccomosaicTMVHowevermedicationsafetydifferentroutesadministrationsmolecularmechanismsbehindscrutinizedfuturestudiesMelittin:venom-derivedpeptidepromisingAnti-viralBeeDrugMelittinVenom

Similar Articles

Cited By